Alvotech, a global biotech company and a subsidiary of Dr. Reddy's Laboratories on Tuesday have entered into a licence and supply agreement for the commercialisation of AVT03, the latter's biosimilar candidate to Prolia and Xgeva (denosumab). A press release from Dr Reddy's said the collaboration combines the city-based drug maker’s global commercial presence with Alvotech’s proven capabilities in